Inhibitor Therapeutics Company Description

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.

It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.

The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019.

Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Inhibitor Therapeutics, Inc.

Country	United States
Founded	1992
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Francis O'Donnell

Contact Details

Address: 3014 West Palmira Avenue Tampa, Delaware 33629-7264 United States
Phone	813 864 2562
Website	inhibitortx.com

Stock Details

Ticker Symbol	INTI
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US45720M1053
SIC Code	2836

Key Executives

Name	Position
Dr. Francis E. O'Donnell Jr., M.D.	Founder, Executive Chairman and Chief Executive Officer
James A. McNulty CPA	Interim Chief Financial Officer, Treasurer and Secretary